<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016779</url>
  </required_header>
  <id_info>
    <org_study_id>812P306</org_study_id>
    <nct_id>NCT04016779</nct_id>
  </id_info>
  <brief_title>Evaluation of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of SPN-812, an extended-release formulation&#xD;
      of viloxazine, in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group&#xD;
      Flexible-Dose Study Evaluating the Efficacy and Safety of SPN-812 in Adults with ADHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">October 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of SPN-812 on ADHD symptoms as assessed by the adult ADHD Investigator Symptom Rating Scale (AISRS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline at End of Study in the AISRS total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on the global assessment of severity of illness as assessed by the Clinical Global Impression - Severity of Illness (CGI-S) Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline at End of Study in the CGI-S total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on the clinical response rate of severity of illness as assessed by the Categorical CGI-S Responder Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of subjects with a CGI-S score of 1 or 2 at End of Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on the global assessment of improvement as assessed by the Clinical Global Impression - Improvement scale (CGI-I)</measure>
    <time_frame>6 weeks</time_frame>
    <description>CGI-I score at End of Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on the clinical response rate of improvement assessed by the Categorical CGI-I Responder Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of subjects with a CGI-I score of 1 or 2 at End of Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on anxiety symptoms as assessed by the Generalized Anxiety Disorder 7 Item scale (GAD-7)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline at End of Study in GAD-7 Total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on ADHD symptoms as assessed by the AISRS Inattention subscale and the AISRS Hyperactivity/Impulsivity subscale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline at End of Study in the AISRS Inattention subscale score and the AISRS Hyperactivity/Impulsivity subscale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on clinical response rate as assessed by AISRS 50% Responder Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of subjects with a 50% or greater reduction in the change from baseline AISRS Total score at End of Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on clinical response rate as assessed by AISRS 30% Responder Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of subjects with a 30% or greater reduction in the change from baseline AISRS Total score at End of Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on executive functioning as assessed by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Global Executive Composite</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline at End of Study in the BRIEF-A Global Executive Composite (GEC) T-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SPN-812 on aspects of executive function and problems of self-regulation as assessed by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Summary Index Scales and BRIEF-A scales</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change from Baseline at End of Study in the BRIEF-A T-score by each Summary Index Scale and by individual BRIEF-A scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPN-812</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPN-812 qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200-600 mg SPN-812</intervention_name>
    <description>200-600 mg SPN-812 will be administered once daily and compared to Placebo</description>
    <arm_group_label>SPN-812</arm_group_label>
    <other_name>SPN-812 Flexible Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is male or female, aged 18 to ≤ 65 years at screening.&#xD;
&#xD;
          2. Is able to read and understand the Informed Consent Form (ICF).&#xD;
&#xD;
          3. Written informed consent obtained from the subject (a signed ICF).&#xD;
&#xD;
          4. Weight within the normal or overweight ranges according to accepted values of the Body&#xD;
             Mass Index Chart (18.0 to 35 kg/m2).&#xD;
&#xD;
          5. Is able to swallow capsules whole, without crushing, chewing or cutting.&#xD;
&#xD;
          6. Is willing and able to attend study appointments within the specified time windows.&#xD;
&#xD;
          7. Has a primary diagnosis of ADHD according to the DSM-5 classification, with diagnosis&#xD;
             made at least 6 months prior to screening and confirmed with Structured Clinical&#xD;
             Interview for DSM-5 Clinical Trials version (SCID-5-CT).&#xD;
&#xD;
          8. Has an AISRS total score of ≥ 26 at the Screening Visit and at the Baseline Visit (V2,&#xD;
             Day 1).&#xD;
&#xD;
          9. Has a CGI-S score of ≥ 4 (moderately ill or worse) at the Screening Visit (V1) and&#xD;
             Baseline Visit (V2, Day 1).&#xD;
&#xD;
         10. Females of childbearing potential (FOCP) must be either sexually inactive (abstinent)&#xD;
             or, if sexually active, must agree to use one of the following acceptable birth&#xD;
             control methods beginning 30 days prior to the first dose of SM and throughout the&#xD;
             study:&#xD;
&#xD;
               1. Simultaneous use of male condom and intra-uterine contraceptive device placed at&#xD;
                  least 4 weeks prior to first SM administration&#xD;
&#xD;
               2. Surgically sterile male partner&#xD;
&#xD;
               3. Simultaneous use of male condom and diaphragm with spermicide&#xD;
&#xD;
               4. Established hormonal contraceptive&#xD;
&#xD;
             Females are considered not to be of childbearing potential if they are either&#xD;
             post-menopausal (amenorrhea for at least 2 years and serum follicle stimulating&#xD;
             hormone (FSH) level of &gt;40 IU/L) or permanently sterilized (e.g., bilateral tubal&#xD;
             ligation, hysterectomy, bilateral oophorectomy for 6 months minimum prior to&#xD;
             screening).&#xD;
&#xD;
         11. Males must:&#xD;
&#xD;
               1. Use 2 methods of contraception in combination if his female partner is of&#xD;
                  childbearing potential; this combination of contraceptive methods must be used&#xD;
                  from the Baseline Visit to ≥ 1 month after the last dose of SM, or&#xD;
&#xD;
               2. Have been surgically sterilized prior to the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has previously enrolled in a SPN-812 study.&#xD;
&#xD;
          2. Is currently participating in another clinical trial or has participated in a clinical&#xD;
             trial within 60 days prior to the first Screening Visit.&#xD;
&#xD;
          3. Is a member of the study personnel or of their immediate families, or is a subordinate&#xD;
             (or immediate family member of a subordinate) to any of the study personnel.&#xD;
&#xD;
          4. Female subjects who are pregnant, lactating and/or sexually active and not agreeing to&#xD;
             use one of the acceptable birth control methods throughout the study.&#xD;
&#xD;
          5. Has history of severe drug allergy or hypersensitivity, or known hypersensitivity, to&#xD;
             the study medication or excipients.&#xD;
&#xD;
          6. Has history of moderate or severe head trauma or other neurological disorder or&#xD;
             systemic medical disease that, in the Investigator's opinion, is likely to affect&#xD;
             central nervous system functioning. This would include subjects with:&#xD;
&#xD;
               1. A current diagnosis of a major neurological disorder; or&#xD;
&#xD;
               2. Seizures, seizure disorder or seizure-like events; or a history of seizure&#xD;
                  disorder within the immediate family (siblings, parents); or&#xD;
&#xD;
               3. Encephalopathy&#xD;
&#xD;
          7. Has any history of schizophrenia, schizoaffective disorder, bipolar disorder,&#xD;
             borderline personality disorder, antisocial personality disorder, narcissistic&#xD;
             personality disorder, autism, post-traumatic stress disorder or obsessive-compulsive&#xD;
             disorder.&#xD;
&#xD;
          8. Has any current psychiatric disorder (per DSM-5 criteria) other than ADHD with the&#xD;
             following exceptions: ADHD is primary diagnoses with comorbidity/secondary diagnoses&#xD;
             of major depression disorder (MDD), nicotine dependence, social anxiety disorder,&#xD;
             generalized anxiety disorder, or phobias, and subject is not receiving pharmacological&#xD;
             treatment for the comorbidity/secondary diagnoses (e.g., antidepressant for MDD) at&#xD;
             time of screening nor for the duration of study.&#xD;
&#xD;
          9. Has a Symptoms of Depression Questionnaire (SDQ) mean score &gt;3.0 at screening.&#xD;
&#xD;
         10. Has a Hamilton Anxiety Rating Scale (HAM-A) score of &gt; 21 at screening.&#xD;
&#xD;
         11. Has organic mental disorders, or mental disorders due to a general medical condition&#xD;
             (per DSM-5 criteria).&#xD;
&#xD;
         12. Has a current diagnosis or history of substance use disorder including alcohol use&#xD;
             disorder (excluding nicotine and caffeine) (per DSM-5 criteria) within the 12 months&#xD;
             prior to screening; or is assessed by the Investigator as having regularly consumed&#xD;
             alcohol exceeding 21 units for males and 14 units for females per week (1 unit equals&#xD;
             340 mL of beer, 115 mL of wine, or 43 mL of spirits) within the 12 months prior to&#xD;
             screening.&#xD;
&#xD;
         13. Is currently using, or has a positive result on the drug screening at the Screening&#xD;
             Visit for drugs of abuse (alcohol, opiates, methadone, cocaine, methamphetamine&#xD;
             [including ecstasy], phencyclidine, propoxyphene, methylphenidate, barbiturates, and&#xD;
             benzodiazepines). If subject's serum drug screen for ethanol is positive at Screening&#xD;
             (V1) and the investigator determines subject does not have alcohol use disorder, then&#xD;
             the subject may have a repeat serum drug screen for ethanol performed before baseline&#xD;
             within the allotted screening period (results must be received prior to V2 baseline).&#xD;
             If second serum drug screen for ethanol is positive, subject is excluded from&#xD;
             participating in the study, however, if second serum drug screen for ethanol is&#xD;
             negative, subject may proceed to V2.&#xD;
&#xD;
         14. Is a (known or self-identified) current habitual/chronic cannabis user (medicinal or&#xD;
             recreational); or&#xD;
&#xD;
               -  Has a positive urine drug screen for cannabis at the Screening Visit and is&#xD;
                  considered, per the Investigator's judgement, to be a habitual/chronic cannabis&#xD;
                  user; or&#xD;
&#xD;
               -  Has a positive urine drug screen for cannabis at both the screening and follow-up&#xD;
                  drug screen at the Baseline Visit, even though the subject is not considered, per&#xD;
                  the Investigator's judgement, to be a habitual/chronic cannabis user.&#xD;
&#xD;
             Note: Subjects who have a positive urine drug screen for cannabis at the Screening&#xD;
             Visit but who are not considered to be a habitual/chronic cannabis user per the&#xD;
             Investigator's judgement may, with Sponsor approval, undergo an additional urine drug&#xD;
             screen at least 4 weeks after the original urine drug screen at Baseline Visit, prior&#xD;
             to randomization. Subjects must agree to refrain from cannabis use throughout study.&#xD;
&#xD;
         15. Has treatment-resistant ADHD based on a history of receipt of &gt;2 approved ADHD&#xD;
             medications that failed to adequately improve the subject's symptoms. A subject who is&#xD;
             naïve to ADHD treatment is not excluded from study participation.&#xD;
&#xD;
         16. Has any other disorder for which its treatment takes priority over treatment of ADHD&#xD;
             or is likely to interfere with study treatment, impair treatment compliance, or&#xD;
             interfere with interpretation of study results.&#xD;
&#xD;
         17. Has history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the&#xD;
             skin that has not been in remission for &gt; 5 years prior to the first dose of SM.&#xD;
&#xD;
         18. Has or has had one or more of the following conditions considered clinically&#xD;
             significant/relevant by the Investigator in the context of the study:&#xD;
&#xD;
               -  cardiovascular disease&#xD;
&#xD;
               -  congestive heart failure&#xD;
&#xD;
               -  cardiac hypertrophy&#xD;
&#xD;
               -  arrhythmia&#xD;
&#xD;
               -  bradycardia (pulse &lt; 50 bpm)&#xD;
&#xD;
               -  tachycardia (pulse &gt; 100 bpm)&#xD;
&#xD;
               -  respiratory disease&#xD;
&#xD;
               -  hepatic impairment or renal insufficiency&#xD;
&#xD;
               -  metabolic disorder&#xD;
&#xD;
               -  endocrine disorder&#xD;
&#xD;
               -  gastrointestinal disorder&#xD;
&#xD;
               -  hematological disorder&#xD;
&#xD;
               -  infectious disorder&#xD;
&#xD;
               -  any clinically significant immunological condition&#xD;
&#xD;
               -  dermatological disorder&#xD;
&#xD;
         19. Exhibits clinically significant abnormal vital signs at screening.&#xD;
&#xD;
         20. Has one or more screening clinical laboratory test values outside the reference range&#xD;
             that, in the opinion of the Investigator, are clinically significant, or any of the&#xD;
             following:&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 times the upper limit of normal (ULN);&#xD;
&#xD;
               -  Serum total bilirubin &gt; 1.5 times ULN;&#xD;
&#xD;
               -  Serum alanine aminotransferase or aspartate aminotransferase &gt; 2 times ULN.&#xD;
&#xD;
         21. Has any of the following cardiology findings at screening:&#xD;
&#xD;
               -  Abnormal ECG that is, in the Investigator's opinion, clinically significant;&#xD;
&#xD;
               -  PR interval &gt; 220 ms;&#xD;
&#xD;
               -  QRS interval &gt; 130 ms;&#xD;
&#xD;
               -  QTcF interval &gt; 450 ms (for men) or &gt; 470 ms (for women) (QT corrected using&#xD;
                  Fridericia's method);&#xD;
&#xD;
               -  Second- or third-degree atrioventricular block;&#xD;
&#xD;
               -  Any rhythm, other than sinus rhythm, that is interpreted by the Investigator to&#xD;
                  be clinically significant.&#xD;
&#xD;
         22. Has any disease or medication that could, in the Investigator's opinion, interfere&#xD;
             with the assessments of safety, tolerability, or efficacy, or interfere with study&#xD;
             conduct or interpretation of results.&#xD;
&#xD;
         23. Evidence of infection with hepatitis B or C, or human immunodeficiency virus (HIV)-1&#xD;
             or HIV-2, as determined by results of testing at screening.&#xD;
&#xD;
         24. Lost or donated more than 450 mL of blood during the 30 days prior to screening.&#xD;
&#xD;
         25. Use of any investigational drug or prohibited concomitant medications including known&#xD;
             CYP1A2 substrates (e.g., theophylline, melatonin) within 30 days or 5 half-lives prior&#xD;
             to Baseline Visit (Day 1) (whichever is longer) during the screening period or&#xD;
             anticipated for the duration of the study.&#xD;
&#xD;
         26. History of unexplained loss of consciousness, unexplained syncope, unexplained&#xD;
             irregular heartbeats or palpitations or near drowning with hospital admission.&#xD;
&#xD;
         27. Has attempted suicide within the 6 months prior to screening, or is at significant&#xD;
             risk of suicide, either in the opinion of the Investigator or defined as a &quot;yes&quot; to&#xD;
             suicidal ideation questions 4 or 5 or answering &quot;yes&quot; to suicidal behavior on the&#xD;
             C-SSRS within the 6 months prior to screening.&#xD;
&#xD;
         28. In the Investigator's opinion, is unlikely to comply with the protocol or is&#xD;
             unsuitable for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Rubin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Research Institue for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Rearch</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network LLC</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psych Atlanta</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates Midwest Research Center</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alivation Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassmann Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioscience Research</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Research Network LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128r</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradigm Research Professionals</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin P.C.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LLP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

